問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Infectious Disease

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間:2023-09-19

盧柏樑Lu, Po-Liang
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

篩選

List

55Cases

2025-01-01 - 2031-01-26

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2017-06-01 - 2019-12-31

Phase II

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia
  • Condition/Disease

    Pseudomonas Aeruginosa Pneumonia

  • Test Drug

    Aerucin(aerubumab,AR-105)

Participate Sites
11Sites

Terminated10Sites

2015-01-02 - 2016-06-30

Phase III

A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/RPX7009) Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Adults
  • Condition/Disease

    Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Adults

  • Test Drug

    Carbavance(meropenem/RPX7009)

Participate Sites
4Sites

Terminated4Sites

2019-05-01 - 2021-12-30

Phase III

A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
  • Condition/Disease

    Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

  • Test Drug

    Sulbactam-ETX2514 (ETX2514SUL)

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites

2012-02-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2022-01-01 - 2025-08-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

陳宜君
National Taiwan University Hospital

Division of Infectious Disease

2021-07-21 - 2023-03-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2012-10-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites